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1. Introduction 
The aggregation of human blood platelets by 
adenosine diphosphate (ADP) is specifically inhibited 
by adenosine and a few related compounds [l-3]. 
While the mode of action of adenosine remains contro- 
versial, investigations have been made with various 
adenosine analogues [4]. The present report is of studies 
with a series of adenosine derivatives which have not 
been tested previously with this system. This group of 
substances contain adenosine molecules joined in 
pairs, by different numbers of phosphate groups, at 
position 5’ of the two ribosyl moieties. They may be 
represented by the formula: 
A -O- 
[ d 
- 0 - A, where A = adenosine and 
11 
n = the number of phosphate groups. 
Evidence is presented which is consistent with the 
idea that adenosine and its derivatives compete with 
ADP at the platelet surface. The inhibitory power of 
these derivatives increases with the value of n up to a 
limitofn=S. 
2. Material and methods 
The preparation of the adenosine phosphate 
derivatives AP,A, AP3A, AP4A, AP5A and AP6A will 
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be described elsewhere [S] . No compound showed any 
ADP or adenosine impurities i.e. no more than 1% 
present. The solutions of the derivatives were frozen 
quickly and held at -20°C when not in use. All other 
chemicals were from commercial sources and of 
analytical grade. All solutions were adjusted to pH 7.4 
and to isosmolarity before use. Both washed platelets 
and platelet rich plasma (PRP) were prepared as 
previously described [6] . Glucose 0.1% (w/v) was 
included in the medium if the platelets were to be 
incubated as long as 30 min. Human fibrinogen at a 
final concentration of 0.5 mg/ml was used with 
washed platelets. A solution of thrombin containing 
6 N.I.H. units/ml was made up daily. To label platelets, 
10 ml plasma were incubated with [3H] serotonin to 
give a final concentration of 0.008 pCi/ml and gently 
shaken at 20°C for 20 min. The platelets were then 
washed. Release experiments were performed by a 
modification [7] of the method of Massini and 
Liischer [8], but with [3H] serotonin instead of 
[ 14C] serotonin. The aggregation and inhibition of 
aggregation of stirred platelets was measured by the 
turbidimetric method [9,10]. Adenylate kinase 
activity was measured by the method of Adam [ 111. 
One unit of adenylate kinase is defined as 2 pmol ADP 
formed per min at 25°C. 
3. Results 
The time dependence and relative activities of 
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Fig.1. 100 JIM concentrations of each of the inhibitors were 
incubated with PRP for different times before 10 ~JM ADP 
was added. The extent of aggregation was measured by the 
&OD. The extent of inhibition of aggregation by the inhibitors 
was calculated by comparison with control platelets, to which 
only ADP was added. 
AP2A, APsA, AP,Aand APsA (100 PM) in the 
inhibition of ADP (10 PM) aggregation in PRP are 
shown in fig. 1. At 30 PM APeA inhibits ADP aggregation 
in PRP slightly less than does AP5 A at the same 
concentration. The adenosine derivatives at 30 MM 
inhibit the aggregation of washed platelets by ADP 
(l-10 PM) and thrombin (0.006-0.06 NIH/ml) and 
by dextran sulphate (1 nM). They do not affect 
DEAE-Dextran (6 nM) aggregation. The extent of the 
inhibition of aggregation is dependent on the dose of 
the inhibitors. For APzA and APsA, inhibition of 
aggregation is also dependent on the time of their 
incubation with the platelets prior to the addition of 
ADP. Fig.2 is typical of several experiments. It shows 
double reciprocal plots of the change in optical density 
of the platelet suspensions with variable ADP con- 
centration and constant concentrations of the different 
inhibitors. The grapla is highly suggestive of similar 
V max values in the control and inhibition experiments, 
indicating competitive inhibition. The figure does not 
give absolute values for Vmax but it indicates the 
relative efficiency of the various compounds to produce 
inhibition. At a given concentration, APsA is the 
strongest inhibitor of ADP aggregation. The inhibitors 
in order of strength are APs A > AP4 A > adenosine> 
ATP > APaA > AP,A. From the intercept on the X 
axis, an approximate value for the apparent dissociation 
constant of the receptors and ADP of 1.25 nM is 
obtained. For APsA at the concentration used, the 
- x 105 
ADP(M) 
Fig.2. 30 PM concentrations of each of the inhibitors were 
incubated for 10 min with washed platelets. Fibrinogen and 
variable concentrations of ADP were added and the changes 
in optical density were measured. Double reciprocal plots were 
made, taking the change in optical density (aOD) in five min 
as the velocity (v) of the inhibition of ADP aggregation. For 
the sake of clarity, only a few values of l/ADP less than 1.0, 
and no standard deviations are shown on the figure. With 
l/ADP at 0.2 X 105 and 0.5 X 10’ the SDS of l/aOD for 
AP,A were 7.7 and 9.2 respectively; for AP,A they were 
1.4 and 0.4. (o)AP,A; (x)AP,A; (n)adenosine; (o)ATP; 
(“)AP,A; + AP,A; (a)ADP. 
inhibition is so strong that a reliable value of the 
intercept can not be obtained. Due to the weaker 
inhibition of AP4A, it is possible to obtain an 
apparent value of its inhibition constant of 700 nM. 
Since APs A inhibits considerably more strongly, it 
appears to have much higher affinity for receptor 
sites than ADP itself or than ATP or adenosine. 
Enzymatic breakdown of APnA compounds to 
adenosine could cause inhibition of platelet aggregation. 
However, incubation of the AP,A compounds (at 1 mM) 
for 10 min with washed platelets or PRP does not 
lead to detectable breakdown as judged by thin layer 
chromatography. Also, incubation of adenosine 
deaminase (40 ng/ml) for 10 min with the AP,A 
compounds at lo-100 PM in the presence of washed 
platelets results in no reduction in the inhibition of 
ADP aggregation. This concentration of deaminase 
hinders the inhibition produced by 20-200 I.IM 
adenosine. 
It is possible that the calcium necessary for platelet 
aggregation might be removed by binding with the 
AP,,A compounds. To test this, the experiments were 
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repeated with five times the usual concentration of 
calcium, i.e. with 5 mM calcium. The extent of inhibi- 
tion of aggregation by the AP,A compounds was not 
altered. 
Washed platelets incubated with 100 /.& AP, A 
give a slow release of serotonin. There was no signifi- 
cant release at 1 mm but 24 + 5% release in 30 min 
(control 17 +- 5%). The reason for this slow release is 
not known. Lower concentrations of APs A do not 
give a release in this time. Without preincubation, 
30 PM APs A inhibits ADP-release in washed platelets 
and PRP by 44% and 55% respectively. At 30 PM, 
AP,A derivatives inhibit the ADP release reaction in 
PRP with diminished strength as n decreases from 
6 (9 1 + 8% inhibition) to 2 (4 + 4% inhibition). 
4. Discussion 
The AP,A derivatives inhibit aggregation in the 
same order of efficiency as they inhibit the enzyme 
activity of adenylate kinase [5,12] i.e. up to n = 5 the 
more phosphat groups, the more inhibitory the activity. 
APSA inhibits ADP aggregation more strongly than does 
AP4A or AP6A. This suggests that the distance between 
the bases in the APS A molecule corresponds most 
satisfactorily to the distance between the ATP and 
AMP binding sites of the enzyme. Adenylate kinase 
occurs in high concentrations in muscle cells where a 
part of it is probably closely associated with actomyosin. 
The nature of this association is not clear (Schirmer, 
1974, personal communication). On the platelet 
surface, the binding site for APs A might be structurally 
related to adenylate kinase. This enzyme has not yet 
been found on the platelet surface [ 131. However it is 
possible that adenylate kinase itself is associated with 
the contractile protein thrombosthenin, which occurs 
partly on the platelet membrane [14]. This adenylate 
kinase could be the target of the diadenosine polyphos- 
phates. We found the enzyme in the supernatant of 
washed platelets, after stirring them for 5 min, at a 
concentrationof 70 mU~lOg platelets. This platelet 
adenylate kinase is inhibited by AP, A in the same way 
as the muscle enzyme. The results of Haslam and Mills 
[ 131 agree well with ours. They found adenylate 
kinase activity at a concentration of 90 mU/ 10’ 
platelets in the suspending medium of washed plate- 
lets which were stirred for 15 min. Due to slightly 
different conditions used for the assay, the values are 
not directly comparable but are in the same range. 
The double reciprocal plots in fig.2 suggest hat 
adenosine, the adenosine derivatives and ATP act 
competitively with ADP. Born [ 151 suggested that 
inhibition by adenosine and its derivatives was due to 
competition between adenosine and ADP at a specific 
receptor site on the platelet membrane. Rozenberg 
and Holmsen [ 161 proposed that the inhibition was 
associated with the process of adenosine uptake by 
platelets with concurrent ATP hydrolysis. This ATP is 
thought to be necessary for the aggregation mechanism. 
However Born and Mills [ 1 ] showed that drugs that 
inhibited uptake of adenosine by platelets did not 
inhibit the action of adenosine on ADP-induced 
aggregation. Later, Born [ 171 suggested that inhibition 
of ADP by adenosine might involve competition for a 
third component, not necessarily at the same binding 
site. Holmsen [ 181 contended that adenosine binds to 
some area of the membrane before it exert its inhibitory 
effect. Once taken up and converted to AMP, adenosine 
might interfere sterically with adenylate kinase, which 
in some way could inhibit ADP-induced aggregation. 
Adenosine may also exert its action through adenylate 
cyclase and the cyclic AMP system [ 19,201. One 
would not expect our group of adenosine derivatives 
to penetrate platelet membrane since all are multivalent- 
negatively charged compounds. Furthermore, the 
immediate effect of these derivatives on some aspect 
of platelet function suggests that they act at the 
membrane level. It is possible that the adenosine poly- 
phosphates could act competitively with ADP, and at 
the same time affect the cyclic AMP system. The latter 
effect would not require penetration of the platelet 
membrane. Further studies which are concerned with 
the effects of these adenosine derivatives on the cyclic 
AMP system, thrombosthenin or ADP receptor sites 
are required. They may help to elucidate the precise 
nature of the inhibitory mechanisms of these dinucleo- 
tide phosphates on ADP-induced platelet aggregation. 
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